Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations, 2018 for the quarter ended on 30.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has submitted a quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30 June 2025. This is a routine procedural filing in which the company's Registrar and Share Transfer Agent (RTA) confirms that dematerialised (demat) shares received from the depository have been properly processed — either cancelled and mutilated in case of transfers, or held in good faith. No financial figures, share counts, or business updates are part of this disclosure.
No material impact on shareholders or the stock price. This is a standard regulatory compliance submission confirming smooth handling of demat share activity and carries no operational or financial signal.